Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
In North America cancer majorly remain one of the most frequent lethal disease. The increasing cases of cancer screening and mortality rate in the developed countries of North America is boosting the demand for precision cancer diagnostic tests market. The new test like precision cancer diagnostic helps for the selection of appropriate treatment based on molecular characteristics of tumor .Moreover, development of specialized cancer center in the region is adding benefit to the growth of the market. Besides increasing innovation and development of new and sensitive cancer diagnostic test to screen and diagnose patient for precise treatment for decreasing the risk of cancer in patient is further driving the market growth. Also, merger and acquisitions among key players in North America is ultimately developing the growth of market and economy.
The market is driven by rising prevalence of cancer cases in North America due to changing lifestyle, smoking, and exposure to carcinogen and smoking. In North America the cancer is major observed in Men than women which further has the demand for precision cancer diagnostic tests. Also, increase in awareness about routine health checkup for early detection of such a diseases is fueling the growth of the market. Besides developed healthcare facilities and diagnostic method is driving the market growth.
The exclusive COVID 19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the North America precision cancer diagnostic tests market. In addition, complete analysis of changes on the North America precision cancer diagnostic tests market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market.
The precision cancer diagnostic tests market is segmented based on product, application and geography.
The precision cancer diagnostic tests is available in market according to various products including imaging, molecular, histology/cytology, tumor marker immunoassays and POC colon cancer tests. Imaging lead in the North America precision cancer diagnostic tests market owing increasing adoption of imaging molecular test. Besides, the potential feature of imaging molecular for detecting tumor and visualizing the expression in tumor is driving the growth of the segment in precision cancer diagnostic tests market
The precision cancer diagnostic tests market find its application in hospital, clinic. Hospital is projected to lead in the North America precision cancer diagnostic tests market attributing to emerging and developed healthcare infrastructure and facilities. Besides advanced diagnostic facilities and increasing patient inflow in hospital for cancer diagnosis is further boosting the growth of the segment in market.
Precision cancer diagnostic tests market is studied for the following countries including U.S., Mexico and Canada. In North America region U.S. is anticipated to dominate in the precision cancer diagnostic tests market. The growth is due increasing number of cases in country and rising awareness for diagnosis of cancer is further propelling the growth of the region. For instance in 2020, United States had 2, 28, 1658 new cases of cancer. Whereas Canada is expected witness growth at highest rate during the forecast period. Besides presence of key players and new product launches is driving the growth of the region in precision cancer diagnostic tests market.
The key players in precision cancer diagnostic tests market are Abbott Laboratories, Agilent Technologies, Becton Dickinson and Company, Bio-Rad Laboratories, Biocept, Cynvenio Biosystems, Danaher Corporation, Exosome Diagnostics, Foundation Medicine, General Electric Company, Genomic Health, Hologic, Illumina, Myriad Genetics, NanoString Technologies, Ortho Clinical Diagnostics and Thermo Fisher Scientific among others.
May 2020: Tempus which is a technology company advancing precision medicine had announced the launch of two new oncology tests designed to equipment physician with more precise genomics data in an effort to improve therapeutic outcomes. The Tempus HRD test identifies the patient homologous recombination deficiency and Tempus TO predict the tissue of origin (TO) for tumors. The product will be launch in U.S.
The report analyses the North America precision cancer diagnostic tests market based on product, application and geography. The precision cancer diagnostic tests is available in market according to various products including imaging molecular, histology/cytology, tumor marker immunoassays and POC colon cancer tests. The precision cancer diagnostic tests market find its application in hospital, clinic. Precision cancer diagnostic tests market is studied for the following countries including U.S., Mexico and Canada
The key players in precision cancer diagnostic tests market are Abbott Laboratories, Agilent Technologies, Becton Dickinson and Company, Bio-Rad Laboratories, Biocept, Cynvenio Biosystems, Danaher Corporation, Exosome Diagnostics, Foundation Medicine, General Electric Company, Genomic Health, Hologic, Illumina, Myriad Genetics, NanoString Technologies, Ortho Clinical Diagnostics and Thermo Fisher Scientific among others.
Why to buy this report:
